阿托莫克西丁对神经性正静性低血压:一个随机,双盲,安慰剂控制的交叉试验
Naome Mwesigwa1, Patricio Millar Vernetti2, Annet Kirabo1
1Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 506 Robinson Research Building, Nashville, TN, 37232-8802, USA.
概括
在一项临床试验中,阿托莫克西丁在四周内没有改善神经性正静性低血压 (nOH) 症状. 这种北上腺素输送抑制剂在缓解nOH症状方面并不优于安慰剂.
科学领域:
- 心血管医学 心血管医学
- 神经学 神经学
- 临床药理学 临床药理学
背景情况:
- 神经性正静性低血压 (nOH) 是一种衰弱的疾病,其特点是站立时血压下降.
- 上腺素载体 (NET) 抑制剂,如阿托莫克赛丁,已经显示出在管理nOH症状方面的潜力.
- 之前的研究表明,单剂量阿托莫克赛丁可以增加血压并缓解nOH症状.
研究的目的:
- 评估在患有神经性正静性低血压 (nOH) 的患者中为期四周的atomoxetine治疗的疗效和安全性.
- 为了确定持续的阿托莫克塞丁给药是否在nOH患者中比安慰剂更能改善症状.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的交叉试验.
- 参与者接受了初始的开放单剂量阶段,随后进行了为期4周的双盲治疗期,比较了atomoxetine和安慰剂.
- 主要终点是两周后使用正静性低血压问卷 (OHQ) 评估的症状改善.
主要成果:
- 在2周和4周的atomoxetine和安慰剂组之间没有观察到OHQ复合得分的显著差异.
- 静止性低血压症状评估 (OHSA) 和静止性低血压每日活动评分 (OHDAS) 也显示,与安慰剂相比,阿托莫克赛丁没有显著改善.
- 研究人员发现,阿托莫克赛丁被研究参与者耐受得很好.
结论:
- 四周的阿托莫克塞丁治疗在改善神经性正静性低血压 (nOH) 症状方面并不优于安慰剂.
- 尽管单剂量研究的初步有希望的结果,但持续的阿托莫克塞丁治疗并没有显示出对nOH症状管理的显著临床益处.
- 阿托莫克赛丁是nOH患者的安全治疗选择,但其对长期缓解症状的有效性需要进一步研究.
更多相关视频
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
9.8K
07:20Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
1.1K
相关概念视频
01:21Drugs Affecting Neurotransmitter Release or Uptake
994
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
994
01:24Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
329
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
329
01:23Antidepressant Drugs: MAOIs and Other Agents
201
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
201
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
274
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
274